[1] Shi XZ, Jin X, Xu P, et al. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a metaanalysis[J]. Asian Pac J Cancer Prev, 2014, 15(16): 6643-6647.
[2] Prinzi N, Sorrenti S, Baldini E, et al. Association of thyroid diseases with primary extrathyroidal malignancies in women: results of a cross-sectional study of 6,386 patients[J]. PLoS One, 2015, 10(3): e122958. DOI: 10.1371/journal.pone.0122958.
[3] Pinter M, Haupt L, Hucke F, et al. The impact of thyroid hormones on patients with hepatocellular carcinoma[J]. PLoS One, 2017, 12(8): e0181878. DOI: 10.1371/journal.pone.0181878.
[4] Borriello A, Caldarelli I, Bencivenga D, et al. Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on selfrenewal, commitment and functions[J]. Oncotarget, 2017, 8(3): 5540-5565. DOI: 10.18632/oncotarget.12649.
[5] Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance[J]. Mol Cancer, 2018, 17(1): 36. DOI: 10.1186/s12943-018-0801-5.
[6] Qin S, Li A, Yi M, et al. Recent advances on antiangiogenesis receptor tyrosine kinase inhibitors in cancer therapy[J]. J Hematol Oncol, 2019, 12(1): 27. DOI: 10.1186/s13045-019-0718-5.
[7] Beukhof CM, van Doorn L, Visser TJ, et al. Sorafenibinduced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma[J]. J Clin Endocrinol Metab, 2017, 102(8): 2922-2929. DOI: 10.1210/jc.2016-4025.
[8] Mondello P, Mian M, Pitini V, et al. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?[J]. Curr Oncol, 2016, 23(3): e165-e170. DOI: 10.3747/co.23.3026.
[9] Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(6): 804-834. DOI: 10.6004/jnccn.2017.0100.
[10] Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell cancer (RCC)[J]. J Clin Oncol, 2008, 26(15_Suppl): 5126. DOI: 10.1200/jco.2008.26.15_suppl.5126.
[11] Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib[J]. World J Urol, 2011, 29(6): 807-813. DOI: 10.1007/s00345-010-0627-2.
[12] Nearchou A, Valachis A, Lind P, et al. Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a literature-based meta-analysis[J]. Clin Genitourin Cancer, 2015, 13(4): 280-286. DOI: 10.1016/j.clgc.2014.10.002.
[13] Lechner MG, Vyas CM, Hamnvik OR, et al. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers[J]. Thyroid, 2018, 28(4): 445-453. DOI: 10.1089/thy.2017.0587.
[14] Wang T, Xia L, Ma S, et al. Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self renewal[J]. Sci Rep, 2016, 6: 25183. DOI: 10.1038/srep25183.
[15] Zhang N, Jin W, Zhou S, et al. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation[J]. Cancer Med, 2018, 7(12): 5870-5878. DOI: 10.1002/cam4.1797.
[16] Chu YD, Lin KH, Huang YH, et al. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib[J]. Asia Pac J Clin Oncol, 2018, 14(5): e341-e351. DOI: 10.1111/ajco.12983.
[17] BudaNowak A, Kucharz J, Dumnicka P, et al. Sunitinibinduced hypothyroidism predicts progressionfree survival in metastatic renal cell carcinoma patients[J]. Med Oncol, 2017, 34(4): 68. DOI: 10.1007/s12032-017-0928-z.
[18] White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer[J]. Expert Opin Drug Discov, 2015, 10(4): 427-439. DOI: 10.1517/17460441.2015.1006194.
[19] De Falco V, Carlomagno F, Li HY, et al. The molecular basis for RET tyrosinekinase inhibitors in thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2017, 31(3): 307-318. DOI: 10.1016/j.beem.2017.04.013.
[20] Drui D, Illouz F, Do Cao C, et al. Expert opinion on thyroid complications of new anticancer therapies: tyrosine kinase inhibitors[J]. Ann Endocrinol (Paris), 2018, 79(5): 569-573. DOI: 10.1016/j.ando.2018.07.003.
[21] Shu M, Zai X, Zhang B, et al. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses[J]. PLoS One, 2016, 11(1): e0147048. DOI: 10.1371/journal.pone.0147048.
[22] Lin HY, Chin YT, Yang YC, et al. Thyroid hormone, cancer, and apoptosis[J]. Compr Physiol, 2016, 6(3): 1221-1237. DOI: 10.1002/cphy.c150035.
[23] Czarnecka AM, Matak D, Szymanski L, et al. Triiodothyronine regulates cell growth and survival in renal cell cancer[J]. Int J Oncol, 2016, 49(4): 1666-1678. DOI: 10.3892/ijo.2016.3668.
[24] Frau C, Loi R, Petrelli A, et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats[J]. Hepatology, 2015, 61(1): 249-259. DOI: 10.1002/hep.27399.
[25] Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair[J]. Endocr Relat Cancer, 2016, 23(8): R353-R369. DOI: 10.1530/ERC-16-0152.
[26] MartinezIglesias O, GarciaSilva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis[J]. Cancer Res, 2009, 69(2): 501-509. DOI: 10.1158/0008-5472.CAN-08-2198.
[27] Chung IH, Chen CY, Lin YH, et al. Thyroid hormonemediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer[J]. Oncotarget, 2015, 6(17): 15050-15064. DOI: 10.18632/oncotarget.3670.
[28] Wu SM, Cheng WL, Liao CJ, et al. Negative modulation of the epigenetic regulator, UHRF1, by thyroid hormone receptors suppresses liver cancer cell growth[J]. Int J Cancer, 2015, 137(1): 37-49. DOI: 10.1002/ijc.29368.
[29] Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase Ⅰ/Ⅱ study[J]. Anticancer Res, 2003, 23(1B): 617-626. |